MCID: GST019
MIFTS: 72

Gastrointestinal Stromal Tumor malady

Categories: Genetic diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Gastrointestinal Stromal Tumor

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 24GeneTests, 25Genetics Home Reference, 26GTR, 30ICD10 via Orphanet, 36MedGen, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Gastrointestinal Stromal Tumor:

Name: Gastrointestinal Stromal Tumor 51 11 24 25 53 69 12 49 13
Gist 11 47 24 25 53 69 13
Gastrointestinal Stromal Sarcoma 47 25 53 67
Gastrointestinal Stromal Tumors 47 26 38 67
Paraganglioma and Gastric Stromal Sarcoma 67
Gastrointestinal Stromal Tumor, Familial 51
 
Gastrointestinal Stromal Tumor, Somatic 51
Stromal Tumor of Gastrointestinal Tract 11
Gastrointestinal Stromal Neoplasm 25
Plexosarcoma 67
Gant 11

Characteristics:

Orphanet epidemiological data:

53
gastrointestinal stromal tumor:
Inheritance: Autosomal dominant,Not applicable; Prevalence: 1-5/10000 (Europe),1-5/10000 (Sweden); Age of onset: Adolescent,Adult,Childhood

HPO:

63
gastrointestinal stromal tumor:
Inheritance: autosomal dominant inheritance, sporadic

Classifications:



External Ids:

OMIM51 606764
Disease Ontology11 DOID:9253
MeSH38 D046152
NCIt44 C3868
Orphanet53 ORPHA44890
MESH via Orphanet39 D046152
UMLS via Orphanet68 C0238198
ICD10 via Orphanet30 C26.9
MedGen36 C0238198

Summaries for Gastrointestinal Stromal Tumor

About this section
OMIM:51 Gastrointestinal stromal tumors are mesenchymal tumors found in the gastrointestinal tract that originate from the... (606764) more...

MalaCards based summary: Gastrointestinal Stromal Tumor, also known as gist, is related to paraganglioma and gastric stromal sarcoma and renal cell carcinoma, and has symptoms including neoplasm of the stomach, sarcoma and nausea and vomiting. An important gene associated with Gastrointestinal Stromal Tumor is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Osteoblast Signaling and Cardiac Progenitor Differentiation. Affiliated tissues include small intestine, liver and colon, and related mouse phenotypes are muscle and normal.

Genetics Home Reference:25 A gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the gastrointestinal tract, most commonly in the stomach or small intestine. The tumors are thought to grow from specialized cells found in the gastrointestinal tract called interstitial cells of Cajal (ICCs) or precursors to these cells. GISTs are usually found in adults between ages 40 and 70; rarely, children and young adults develop these tumors. The tumors can be cancerous (malignant) or noncancerous (benign).

NIH Rare Diseases:47 Gastrointestinal stromal tumors are a type of soft tissue sarcoma (tumor) that usually begins in cells in the wall of the stomach, intestines, or rectum. These tumors may be noncancerous or cancerous. They can affect adults, adolescents, or children.  It is estimated that around 5,000 new cases of gastrointestinal stromal tumors are diagnosed in the United States each year. Last updated: 4/27/2010

UniProtKB/Swiss-Prot:69 Gastrointestinal stromal tumor: Common mesenchymal neoplasms arising in the gastrointestinal tract, most often in the stomach. They are histologically, immunohistochemically, and genetically different from typical leiomyomas, leiomyosarcomas, and schwannomas. Most GISTs are composed of a fairly uniform population of spindle-shaped cells. Some tumors are dominated by epithelioid cells or contain a mixture of spindle and epithelioid morphologies. Primary GISTs in the gastrointestinal tract commonly metastasize in the omentum and mesenteries, often as multiple nodules. However, primary tumors may also occur outside of the gastrointestinal tract, in other intra-abdominal locations, especially in the omentum and mesentery.

Wikipedia:70 Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the... more...

Related Diseases for Gastrointestinal Stromal Tumor

About this section

Diseases related to Gastrointestinal Stromal Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 306)
idRelated DiseaseScoreTop Affiliating Genes
1paraganglioma and gastric stromal sarcoma33.1SDHA, SDHB, SDHC, SDHD
2renal cell carcinoma30.4FLT3, KIT, PDGFRB, SDHB, SDHD, VIM
3pheochromocytoma30.2ENO2, SDHA, SDHB, SDHC, SDHD
4myelodysplastic syndrome29.6ABL1, CD34, FLT3, KIT, KITLG, PDGFRB
5plexosarcoma11.0
62q33.1 microdeletion syndrome11.0ENO2, VIM
7myxoid leiomyosarcoma10.9CD34, KIT
8xq12-q13.3 duplication syndrome10.9ACTC1, DES, KIT
9harding ataxia10.9DES, VIM
10lymphangiomatosis10.9ACTC1, VIM
11relapsing epidemic typhus10.9KIT, PDGFRA, S100B
12rectum carcinoma in situ10.9CD34, KIT
13torticollis, familial10.9SDHB, SDHC, SDHD
14carcinoid tumors, intestinal10.9SDHB, SDHC, SDHD
15focal chorioretinitis10.9DES, KIT, VIM
16retinoschisis autosomal dominant10.9SDHB, SDHD
17seminal vesicle cystadenoma10.9SDHB, SDHC, SDHD
18hypotonia10.9S100B, VIM
19uterine corpus endometrial carcinoma10.9SDHB, SDHC, SDHD
20transverse colon cancer10.9ACTC1, PDGFRA, SDHB
21absence of fingerprints congenital milia10.9DES, S100B, VIM
22skin lipoma10.9ACTC1, DES, VIM
23breast rhabdomyosarcoma10.9CD34, DES, KIT
24mollaret meningitis10.9ACTC1, DES, VIM
25acquired porencephaly10.9PDGFRA, PDGFRB
26infantile glycine encephalopathy10.9ACTC1, S100B
27bartholin's gland benign neoplasm10.9DES, S100B, VIM
28malignant adenofibroma10.9DES, S100B, VIM
29sclerosing liposarcoma10.9DES, S100B, VIM
30leiomyoma cutis10.9CD34, KIT
31epithelioid cell melanoma10.9KIT, S100B, VIM
32sporadic secreting paraganglioma10.9SDHB, SDHC, SDHD
33congenital disorder of glycosylation, type iq10.9KIT, PDGFRA, PDGFRB
34anaplastic oligoastrocytoma10.9S100B, VIM
35intravascular fasciitis10.9ACTC1, CD34, DES
36myxoid liposarcoma of the ovary10.9ACTC1, CD34, VIM
37short-rib thoracic dysplasia 1210.9ACTC1, DES, VIM
38malignant fibrous histiocytoma of bone10.8CD34, KIT, PDGFRA
39tooth erosion10.8CD34, KIT, VIM
40eccrine papillary adenoma10.8ACTC1, S100B, VIM
41prostate small cell carcinoma10.8ENO2, KIT, PDGFRA
42staphyloenterotoxemia10.8ACTC1, DES, VIM
43pineal parenchymal tumor of intermediate differenciation10.8ACTC1, S100B, VIM
44mushroom workers' lung10.8ACTC1, S100B
45epithelioid leiomyosarcoma10.8ENO2, KIT, PDGFRA
46mild phosphoribosylpyrophosphate synthetase superactivity10.8ACTC1, DES, VIM
47pura syndrome10.8ACTC1, DES, KIT, PDGFRA
48isolated ectopia lentis10.8DES, ENO2
49gallbladder angiosarcoma10.8CD34, KIT
50lymphocytic vasculitis10.8DES, VIM

Graphical network of the top 20 diseases related to Gastrointestinal Stromal Tumor:



Diseases related to gastrointestinal stromal tumor

Symptoms for Gastrointestinal Stromal Tumor

About this section

Symptoms by clinical synopsis from OMIM:

606764

Clinical features from OMIM:

606764

Human phenotypes related to Gastrointestinal Stromal Tumor:

 63 53 (show all 23)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the stomach63 53 hallmark (90%) Very frequent (99-80%) HP:0006753
2 sarcoma63 53 hallmark (90%) Very frequent (99-80%) HP:0100242
3 nausea and vomiting63 53 typical (50%) Frequent (79-30%) HP:0002017
4 constipation63 53 typical (50%) Frequent (79-30%) HP:0002019
5 gastrointestinal hemorrhage63 53 typical (50%) Frequent (79-30%) HP:0002239
6 intestinal obstruction63 53 typical (50%) Frequent (79-30%) HP:0005214
7 feeding difficulties in infancy63 typical (50%) HP:0008872
8 skin rash63 53 occasional (7.5%) Occasional (29-5%) HP:0000988
9 abnormality of the liver63 53 occasional (7.5%) Occasional (29-5%) HP:0001392
10 anemia63 53 occasional (7.5%) Occasional (29-5%) HP:0001903
11 irregular hyperpigmentation63 53 occasional (7.5%) Occasional (29-5%) HP:0007400
12 neoplasm of the colon63 53 occasional (7.5%) Occasional (29-5%) HP:0100273
13 neoplasm of the rectum63 53 occasional (7.5%) Occasional (29-5%) HP:0100743
14 esophageal neoplasm63 53 occasional (7.5%) Occasional (29-5%) HP:0100751
15 neoplasm of the small intestine63 53 occasional (7.5%) Occasional (29-5%) HP:0100833
16 hyperpigmentation of the skin63 HP:0000953
17 urticaria63 HP:0001025
18 neurofibromas63 HP:0001067
19 large hands63 HP:0001176
20 dysphagia63 53 Frequent (79-30%) HP:0002015
21 gastrointestinal stroma tumor63 53 Very frequent (99-80%) HP:0100723
22 neoplasm of the gastrointestinal tract53 Occasional (29-5%)
23 fatigue53 Frequent (79-30%)

Drugs & Therapeutics for Gastrointestinal Stromal Tumor

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Gleevec16 43 IMATINIB MESYLATE Novartis May 2001
FDA Label: Gleevec
Disease/s that Drug Treats:chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:16 Gleevec™ (imatinib mesylate) is indicated for the treatment of newly diagnosed adultpatients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronicphase. Follow-up is limited. Page 10Gleevec is also indicated for the treatment of patients with Philadelphia chromosomepositive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronicphase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment ofpediatric patients with Ph+ chronic phase CML whose disease has recurred after stem celltransplant or who are resistant to interferon alpha therapy. There are no controlled trialsdemonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.Gleevec is also indicated for the treatment of patients with Kit (CD117) positiveunresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (SeeCLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec inGIST is based on objective response rate (see CLINICAL STUDIES). There are no controlledtrials demonstrating a clinical benefit, such as improvement in disease-related symptoms orincreased survival.
DrugBank Targets:14 1. BCR/ABL fusion protein isoform X9;2. Mast/stem cell growth factor receptor Kit;3. RET proto-oncogene;4. High affinity nerve growth factor receptor;5. Macrophage colony-stimulating factor 1 receptor;6. Platelet-derived growth factor receptor alpha;7. Epithelial discoidin domain-containing receptor 1;8. Tyrosine-protein kinase ABL1;9. Platelet-derived growth factor receptor beta
Mechanism of Action:16 
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosinekinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosomeabnormality in chronic myeloid leukemia (CML). It inhibits proliferation and inducesapoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphiachromosome positive chronic myeloid leukemia. In colony formation assays using ex vivoperipheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positivecolonies from CML patients.In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as wellas Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derivedgrowth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- andSCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis ingastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
2
Stivarga16 43 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
FDA Label: Stivarga
Disease/s that Drug Treats:gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:16 Stivarga is a kinase inhibitor indicated for the treatment of patients with: Metastatic colorectal cancer (CRC) who have been previously treated withfluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGFtherapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1) Locally advanced, unresectable or metastatic gastrointestinal stromal tumor(GIST) who have been previously treated with imatinib mesylate andsunitinib malate. (1.2)
DrugBank Targets:14 1. Proto-oncogene tyrosine-protein kinase receptor Ret;2. Vascular endothelial growth factor receptor 1;3. Vascular endothelial growth factor receptor 2;4. Vascular endothelial growth factor receptor 3;5. Mast/stem cell growth factor receptor Kit;6. Platelet-derived growth factor receptor alpha;7. Platelet-derived growth factor receptor beta;8. Fibroblast growth factor receptor 1;9. Fibroblast growth factor receptor 2;10. Angiopoietin-1 receptor;11. Discoidin domain-containing receptor 2;12. High affinity nerve growth factor receptor;13. Ephrin type-A receptor 2;14. RAF proto-oncogene serine/threonine-protein kinase;15. Serine/threonine-protein kinase B-raf;16. Mitogen-activated protein kinase 11;17. Tyrosine-protein kinase FRK;18. Tyrosine-protein kinase ABL1
Mechanism of Action:16 
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normalcellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumormicroenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 andM-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib thathave been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some forhuman colorectal carcinoma.
3
Sutent16 43 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:16 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:14 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:16 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
4
Votrient16 43 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009
FDA Label: Votrient
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:16 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:14 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:16 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.

Drugs for Gastrointestinal Stromal Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 201)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Oxaliplatinapproved, investigationalPhase 4, Phase 1141261825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
2
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1500341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
3
Sirolimusapproved, investigationalPhase 4, Phase 1, Phase 2189653123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
4
EverolimusapprovedPhase 4, Phase 1, Phase 21896159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
5
Midazolamapproved, illicitPhase 4, Phase 168459467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
6
Esomeprazoleapproved, investigationalPhase 4324161796-78-7, 119141-88-74594, 9579578
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(-)-omeprazole
(S)-(-)-Omeprazole
(S)-(−)-omeprazole
(S)-Omeprazole
(S)-omeprazole
(s)-omeprazole
(−)-omeprazole
119141-88-7
119141-89-8
131959-78-9
172964-80-6
193469-77-1
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
326602-80-6
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-methoxy-2-{(S)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1-methyl-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
6-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
73590-58-6
AC-401
AC1L1IIJ
AGI-010
AKOS005066653
AULCER
Antra
Antra MUPS
Audazol
Axagon
BIDD:GT0020
BIDD:GT0189
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
Belmazol
Bio-0888
C07324
CAS-73590-58-6
CCRIS 7099
CHEBI:50275
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CID9568614
CID9579578
CPD000058847
Ceprandal
D00455
D07917
DB00338
DB00736
DM-3458
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Esomeprazol
Esomeprazole
Esomeprazole (INN)
Esomeprazole Sodium
Esomeprazole [INN:BAN]
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168-68
H 168/68
H-168/68
H168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20
Indurgan
Inexium paranova
Inexium paranova (TN)
Inhibitron
Inhipump
LS-185188
LS-7629
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
Lucen
MLS000069373
MLS001076112
MLS001424148
Maybridge4_002645
Mepral
 
Miol
Miracid
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
MolPort-005-943-880
Mopral
Morecon
NCGC00016925-01
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium Control
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
OMEP
OMZ
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole (JAN/USP/INN)
Omeprazole S-form
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prestwick_808
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
SMR000058847
SPBio_002306
STK623746
Sanamidol
Secrepina
TL8005099
Tedec Ulceral
UNII-KG60484QX9
UNII-N3PA6559FT
UPCMLD-DP075
UPCMLD-DP075:001
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
ZINC04693574
ZINC04693575
Zefxon
Zegerid
Zepral
Zimor
Zoltum
esomeprazol
esomeprazole
esomeprazolum
omeprazole
Ésoméprazole
7
Caffeineapproved, NutraceuticalPhase 438058-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffeinum
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
 
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
teína
8Imatinib MesylatePhase 4, Phase 3, Phase 2, Phase 1594123596
9AnestheticsPhase 4, Phase 3, Phase 1, Phase 29001
10Angiogenesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14143
11Pharmaceutical SolutionsPhase 4, Phase 37793
12Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 13612
13Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 13868
14Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 2, Phase 14072
15Phosphodiesterase InhibitorsPhase 41254
16Neurotransmitter AgentsPhase 4, Phase 3, Phase 117734
17Psychotropic DrugsPhase 4, Phase 16279
18Tranquilizing AgentsPhase 4, Phase 14164
19Gastrointestinal AgentsPhase 4, Phase 3, Phase 28109
20Hypnotics and SedativesPhase 4, Phase 12485
21Adjuvants, AnesthesiaPhase 4, Phase 3, Phase 11588
22Purinergic P1 Receptor AntagonistsPhase 4348
23Central Nervous System DepressantsPhase 4, Phase 3, Phase 112806
24Immunosuppressive AgentsPhase 4, Phase 1, Phase 212770
25Anesthetics, IntravenousPhase 4, Phase 3, Phase 12406
26Central Nervous System StimulantsPhase 42132
27
Erlotinib HydrochloridePhase 4, Phase 1798183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
28Anesthetics, GeneralPhase 4, Phase 3, Phase 12787
29GABA AgentsPhase 4, Phase 11622
30GABA ModulatorsPhase 4, Phase 1864
31Anti-Anxiety AgentsPhase 4, Phase 11816
32
Proton pump inhibitorsPhase 4, Phase 11080
Synonyms:
 
PPIs
33Anti-Ulcer AgentsPhase 41767
34AntacidsPhase 41767
35ColaNutraceuticalPhase 4, Phase 3, Phase 2, Phase 11881
36
Bevacizumabapproved, investigationalPhase 3, Phase 2, Phase 11968216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
37
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
38
Dasatinibapproved, investigationalPhase 3, Phase 2, Phase 1281302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
39
Formaldehydeapproved, vet_approvedPhase 38450-00-0712
Synonyms:
Aldeide formica
Fannoform
Formaldehyde
Formalin
Formalina
Formaline
Formalith
Formic aldehyde
Formol
 
Methaldehyde
Methanal
Methyl aldehyde
Methylene glycol
Methylene oxide
Oxomethane
Oxomethylene
Oxymethylene
Paraform
Paraformaldehyde
40
MentholapprovedPhase 323532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
41
HistamineapprovedPhase 3103475614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
42
CyproheptadineapprovedPhase 320129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
 
Cyproheptadine (INN)
Cyproheptadine Hcl
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
43
Histamine PhosphateapprovedPhase 3103351-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
44Calcium, DietaryPhase 3, Phase 15525
45NarcoticsPhase 33486
46
crenolanibPhase 3, Phase 21610366136
Synonyms:
 
CP-868569
crenolanib
47pancreatic polypeptidePhase 3, Phase 120
48Peripheral Nervous System AgentsPhase 3, Phase 222776
49Immunoglobulin GPhase 3265
50Endothelial Growth FactorsPhase 3, Phase 2362

Interventional clinical trials:

(show top 50)    (show all 273)
idNameStatusNCT IDPhase
1Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsUnknown statusNCT00777504Phase 4
2Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerUnknown statusNCT00274885Phase 4
3Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorCompletedNCT00793871Phase 4
4Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)CompletedNCT01172548Phase 4
5Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT00171977Phase 4
6Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib MesylateCompletedNCT00510354Phase 4
7Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
8The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of RegorafenibRecruitingNCT02800330Phase 4
9Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With NilotinibActive, not recruitingNCT00756509Phase 4
10Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial TumorsEnrolling by invitationNCT02884154Phase 4
11Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study TerminationNo longer availableNCT01613053Phase 4
12Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644Phase 4
13Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on ImatinibTerminatedNCT00461929Phase 4
14Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorUnknown statusNCT00685828Phase 3
15Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorUnknown statusNCT00103168Phase 3
16A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical TreatmentUnknown statusNCT00812240Phase 3
17A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibUnknown statusNCT01694277Phase 3
18Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceUnknown statusNCT02009423Phase 3
19Caphosol in Oral Mucositis Due to Targeted TherapyUnknown statusNCT01265810Phase 3
20Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By SurgeryCompletedNCT00041197Phase 3
21Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorCompletedNCT00324987Phase 3
22Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal TumorsCompletedNCT00293124Phase 3
23A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)CompletedNCT00075218Phase 3
24Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.CompletedNCT01289028Phase 3
25Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2, Phase 3
26Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)CompletedNCT01462994Phase 3
27Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and SunitinibCompletedNCT00471328Phase 3
28Rechallenge of Imatinib in GIST Having no Effective TreatmentCompletedNCT01151852Phase 3
29A Study of Nilotinib Versus Imatinib in GIST PatientsCompletedNCT00785785Phase 3
30Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs MaintenanceCompletedNCT00367861Phase 3
31Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)CompletedNCT00116935Phase 3
32Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
33Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative ColitisCompletedNCT00033943Phase 2, Phase 3
34Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)RecruitingNCT02260505Phase 3
35EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELsRecruitingNCT02866045Phase 3
36Randomized Trial of Crenolanib in Subjects With D842V Mutated GISTRecruitingNCT02847429Phase 3
37Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTRecruitingNCT02413736Phase 3
38A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHDRecruitingNCT02336230Phase 3
39Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)Active, not recruitingNCT01271712Phase 3
40Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade IndexNot yet recruitingNCT02576080Phase 3
41A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal CancerNot yet recruitingNCT02773524Phase 3
42Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard TherapyNo longer availableNCT01646593Phase 3
43Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib MesylateTerminatedNCT00956072Phase 3
44Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal TumorTerminatedNCT00009906Phase 3
45Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal TumorsTerminatedNCT00372567Phase 3
46Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 MgTerminatedNCT00751036Phase 3
47Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) PatientsTerminatedNCT01031628Phase 3
48Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and SunitinibTerminatedNCT00688766Phase 3
49Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
50A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibUnknown statusNCT01506336Phase 2

Search NIH Clinical Center for Gastrointestinal Stromal Tumor


Cochrane evidence based reviews: gastrointestinal stromal tumors

Genetic Tests for Gastrointestinal Stromal Tumor

About this section

Genetic tests related to Gastrointestinal Stromal Tumor:

id Genetic test Affiliating Genes
1 Gastrointestinal Stromal Tumor26 24 KIT, PDGFRA, SDHB, SDHC

Anatomical Context for Gastrointestinal Stromal Tumor

About this section

MalaCards organs/tissues related to Gastrointestinal Stromal Tumor:

35
Small intestine, Liver, Colon, Endothelial, Myeloid, Lung, Smooth muscle

Animal Models for Gastrointestinal Stromal Tumor or affiliated genes

About this section

MGI Mouse Phenotypes related to Gastrointestinal Stromal Tumor:

40 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053699.9ABL1, ACTC1, DES, ETV1, KIT, PDGFRA
2MP:00028739.7ABL1, ACTC1, ETV1, KIT, NTRK3, PDGFRA
3MP:00053859.3ABL1, ACTC1, DES, KIT, KITLG, NTRK3
4MP:00036319.3ABL1, ENO2, ETV1, KIT, KITLG, MTHFR
5MP:00053849.1ABL1, ACTC1, CD34, DES, ENO2, ETV1
6MP:00053789.0ABL1, ACTC1, ENO2, ETV1, FLT3, KIT
7MP:00107688.7ABL1, ACTC1, DES, ETV1, FLT3, KIT
8MP:00053768.7ABL1, ACTC1, CD34, DES, FLT3, KIT

Publications for Gastrointestinal Stromal Tumor

About this section

Articles related to Gastrointestinal Stromal Tumor:

(show top 50)    (show all 1319)
idTitleAuthorsYear
1
Sphincter-saving resection by cluneal arched skin incision for a gastrointestinal stromal tumor (GIST) of the lower rectum: a case report. (28058590)
2017
2
Clinicopathologic features and prognosis of primary gastrointestinal stromal tumor patients under 35 years of age: A 10-year retrospective study. (27664034)
2016
3
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. (27154065)
2016
4
Gastric Schwannoma mimicking malignant gastrointestinal stromal tumor and misdiagnosed by (18)F-FDG PET/CT. (25840576)
2015
5
PDGFRA Regulates Proliferation of Gastrointestinal Stromal Tumor Cells with Mutations in KIT by Stabilizing ETV1. (25865047)
2015
6
Chromosomal aberrations in primary PDGFRA-mutated gastrointestinal stromal tumors. (24157063)
2014
7
Unusual presentation of a gastrointestinal stromal tumor of the duodenum mimicking an inflammatory enlargement of a peripancreatic lymph node. (25332073)
2014
8
CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. (24726140)
2014
9
Gastrointestinal stromal tumor of small intestine and synchronous bilateral papillary renal cell carcinoma. (24195178)
2013
10
Gastrointestinal stromal tumor: an unusual cause of gastrointestinal bleeding. (23633157)
2013
11
Gastrointestinal stromal tumor with dedifferentiation to undifferentiated pleomorphic sarcoma. (24200161)
2013
12
Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. (23833305)
2013
13
Surgicel(Ar) (oxidized regenerated cellulose) granuloma mimicking local recurrent gastrointestinal stromal tumor: A case report. (23759739)
2013
14
Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. (23281253)
2013
15
Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor. (23352855)
2013
16
Surgical treatment of a giant mesenteric fibromatosis mimicking a gastrointestinal stromal tumor: a case report and current treatment aspects. (23175930)
2012
17
A rare case of acute pancreatitis induced by a gastrointestinal stromal tumor arising from the gastric fundus. (23258486)
2012
18
Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study. (21658742)
2011
19
Gastrointestinal stromal tumor presenting as dyspareunia. (22234771)
2011
20
Unusual metastases of gastrointestinal stromal tumor and genotypic correlates: Case report and review of the literature. (22811827)
2011
21
Gastrointestinal stromal tumor presenting as a rectovaginal mass. Clinicopathologic and molecular-genetic characterization of a rare tumor with a literature review. (21237497)
2011
22
First report of connexin 43-positive gastrointestinal stromal tumor (GIST). (21462830)
2010
23
Is laparoscopic resection the appropriate management of a jejunal gastrointestinal stromal tumor (GIST)? Report of a case. (20975491)
2010
24
Towards global consensus in the treatment of gastrointestinal stromal tumor. (20131998)
2010
25
Gastrointestinal stromal tumor and gastric adenocarcinoma collision tumors. (20381123)
2010
26
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. (19903850)
2009
27
Perioperative treatment of gastrointestinal stromal tumors. (19283922)
2009
28
PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors. (18547963)
2008
29
Gastrointestinal stromal tumors: past, present, and future. (18648736)
2008
30
HER-2 status in gastrointestinal stromal tumor. (18620996)
2008
31
Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. (18510377)
2008
32
Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. (18347171)
2008
33
Gastrointestinal Stromal Tumors (GIST) and Their Management. (19360154)
2007
34
Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation. (17824795)
2007
35
Gastrointestinal stromal tumors--microscopic and immunihistochemical features]. (17969814)
2007
36
Coexistence of papillary renal cell carcinoma and gastrointestinal stromal tumor in a case. (17450496)
2007
37
Estrogen and progesterone receptors expression in gastrointestinal stromal tumors and intramural gastrointestinal leiomyomas. (17992477)
2006
38
Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. (15845570)
2005
39
Malignant epithelioid gastrointestinal stromal tumors: report of a case with cytologic and immunohistochemical studies. (16124176)
2005
40
Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. (16278376)
2005
41
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. (15070666)
2004
42
Malignant gastrointestinal stromal tumor originating in the lesser omentum, complicated by rapidly progressive glomerulonephritis and gastric carcinoma. (15005250)
2004
43
Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. (15232741)
2004
44
Malignant gastrointestinal leiomyosarcoma and gastrointestinal stromal tumor with prominent osteoclast-like giant cells. (15043462)
2004
45
Neurofibromatosis with gastrointestinal stromal tumors: insights into the association. (15387340)
2004
46
PDGFRA activating mutations in gastrointestinal stromal tumors. (12522257)
2003
47
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. (12374669)
2002
48
C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal. (10665649)
1999
49
Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. (10086344)
1999
50
Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. (10199467)
1999

Variations for Gastrointestinal Stromal Tumor

About this section

UniProtKB/Swiss-Prot genetic disease variations for Gastrointestinal Stromal Tumor:

69
id Symbol AA change Variation ID SNP ID
1KITp.Lys550IleVAR_033123rs28933968
2KITp.Val559AlaVAR_033126rs121913517
3KITp.Val559AspVAR_033127rs121913517
4PDGFRAp.Tyr849CysVAR_066474

Clinvar genetic disease variations for Gastrointestinal Stromal Tumor:

5 (show all 41)
id Gene Variation Type Significance SNP ID Assembly Location
1SDHBNM_003000.2(SDHB): c.725G> A (p.Arg242His)SNVPathogenicrs74315368GRCh37Chr 1, 17349143: 17349143
2SDHBSDHB, IVS1DS, G-T, +1SNVPathogenicChr na, -1: -1
3SDHBSDHB, IVS4DS, G-C, +1SNVPathogenicChr na, -1: -1
4PDGFRANM_006206.4(PDGFRA): c.2525A> T (p.Asp842Val)SNVPathogenicrs121908585GRCh37Chr 4, 55152093: 55152093
5PDGFRANM_006206.4(PDGFRA): c.2526_2537delCATCATGCATGA (p.Ile843_Asp846del)deletionPathogenicrs587776792GRCh38Chr 4, 54285927: 54285938
6PDGFRANM_006206.4(PDGFRA): c.2533_2544delCATGATTCGAAC (p.His845_Asn848del)deletionPathogenicrs587776793GRCh37Chr 4, 55152101: 55152112
7PDGFRANM_006206.4(PDGFRA): c.1682T> A (p.Val561Asp)SNVPathogenicrs121908586GRCh37Chr 4, 55141036: 55141036
8PDGFRANM_006206.4(PDGFRA): c.1681_1682insAGAGGG (p.Arg560_Val561insGluArg)insertionPathogenicrs587776794GRCh38Chr 4, 54274868: 54274869
9PDGFRANM_006206.4(PDGFRA): c.1679_1693delGGGTCATTGAATCAA (p.Arg560_Ser564del)deletionPathogenicrs587776795GRCh38Chr 4, 54274866: 54274880
10PDGFRANM_006206.4(PDGFRA): c.1696_1713del18 (p.Ser566_Glu571del)deletionPathogenicrs121913271GRCh38Chr 4, 54274883: 54274900
11KITNM_000222.2(KIT): c.1676_1681delTTGTTG (p.Val559_Val560del)deletionPathogenicrs587776803GRCh38Chr 4, 54727444: 54727449
12KITNM_000222.2(KIT): c.1652_1666delCCATGTATGAAGTAC (p.Pro551_Val555del)deletionPathogenicrs587776804GRCh37Chr 4, 55593586: 55593600
13KITKIT, 15-BP DEL/LYS550ILEdeletionPathogenicChr na, -1: -1
14KITNM_000222.2(KIT): c.1676T> A (p.Val559Asp)SNVPathogenicrs121913517GRCh37Chr 4, 55593610: 55593610
15KITNM_000222.2(KIT): c.1648_1674del27 (p.Lys550_Lys558del)deletionPathogenicrs121913234GRCh38Chr 4, 54727416: 54727442
16SDHBNM_003000.2(SDHB): c.136C> T (p.Arg46Ter)SNVPathogenicrs74315370GRCh38Chr 1, 17044825: 17044825
17SDHBNM_003000.2(SDHB): c.72+1G> TSNVPathogenicrs587782703GRCh38Chr 1, 17053947: 17053947
18SDHCNM_003001.3(SDHC): c.397C> T (p.Arg133Ter)SNVPathogenicrs764575966GRCh37Chr 1, 161326622: 161326622
19SDHBNM_003000.2(SDHB): c.137G> A (p.Arg46Gln)SNVPathogenicrs772551056GRCh37Chr 1, 17371319: 17371319
20SDHBNM_003000.2(SDHB): c.418G> T (p.Val140Phe)SNVLikely pathogenic, Pathogenicrs267607032GRCh37Chr 1, 17355100: 17355100
21KITNM_000222.2(KIT): c.1669_1674delTGGAAG (p.Trp557_Lys558del)deletionLikely pathogenicrs869025568GRCh38Chr 4, 54727437: 54727442
22SDHBNM_003000.2(SDHB): c.-151-?_*159+?deldeletionPathogenicChr na, -1: -1
23SDHBNM_003000.2(SDHB): c.126delT (p.Phe42Leufs)deletionPathogenicrs878854572GRCh38Chr 1, 17044835: 17044835
24SDHBNM_003000.2(SDHB): c.271A> T (p.Arg91Ter)SNVPathogenicrs878854575GRCh38Chr 1, 17033075: 17033075
25SDHCNM_003001.3(SDHC): c.406-?_*2318+?deldeletionPathogenicChr na, -1: -1
26SDHDNM_003002.3(SDHD): c.-84-?_*831+?deldeletionPathogenicChr na, -1: -1
27SDHDNM_003002.3(SDHD): c.10dupC (p.Leu4Profs)duplicationPathogenicrs878854589GRCh37Chr 11, 111957641: 111957641
28SDHDNM_003002.3(SDHD): c.173delG (p.Gly58Alafs)deletionPathogenicrs878854590GRCh37Chr 11, 111959594: 111959594
29SDHDNM_003002.3(SDHD): c.242delC (p.Pro81Argfs)deletionPathogenicrs878854591GRCh38Chr 11, 112088939: 112088939
30SDHBNM_003000.2(SDHB): c.201-?_765+?dupduplicationLikely pathogenicChr na, -1: -1
31SDHBNM_003000.2(SDHB): c.423+1G> ASNVPathogenicrs398122805GRCh37Chr 1, 17355094: 17355094
32MTHFRNM_005957.4(MTHFR): c.665C> T (p.Ala222Val)SNVdrug responsers1801133GRCh37Chr 1, 11856378: 11856378
33MTHFRNM_005957.4(MTHFR): c.1286A> C (p.Glu429Ala)SNVdrug responsers1801131GRCh37Chr 1, 11854476: 11854476
34SDHCNM_003001.3(SDHC): c.43C> T (p.Arg15Ter)SNVPathogenicrs201286421GRCh37Chr 1, 161293426: 161293426
35SDHBNM_003000.2(SDHB): c.575G> C (p.Cys192Ser)SNVLikely pathogenicrs397516835GRCh37Chr 1, 17350535: 17350535
36SDHDNM_003002.3(SDHD): c.112C> T (p.Arg38Ter)SNVPathogenicrs80338843GRCh37Chr 11, 111958640: 111958640
37SDHDNM_003002.3(SDHD): c.242C> T (p.Pro81Leu)SNVPathogenicrs80338844GRCh37Chr 11, 111959663: 111959663
38SDHDNM_003002.3(SDHD): c.274G> T (p.Asp92Tyr)SNVPathogenicrs80338845GRCh37Chr 11, 111959695: 111959695
39SDHDNM_003002.3(SDHD): c.57delG (p.Leu20Cysfs)deletionPathogenicrs587776649GRCh38Chr 11, 112087861: 112087861
40MTRRNM_002454.2(MTRR): c.66A> G (p.Ile22Met)SNVdrug responsers1801394GRCh37Chr 5, 7870973: 7870973
41SDHCNM_003001.3(SDHC): c.405+1G> ASNVLikely pathogenic, Pathogenicrs587776653GRCh37Chr 1, 161326631: 161326631

Cosmic variations for Gastrointestinal Stromal Tumor:

8 (show top 50)    (show all 128)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1260KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1679T>Gp.V560G21
2COSM1252KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1676T>Ap.V559D21
3COSM1183KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1654A>Cp.M552L21
4COSM1257KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1679T>Ap.V560D21
5COSM22414PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1977C>Gp.N659K21
6COSM739PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,epithelioidc.1682T>Ap.V561D21
7COSM1216KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1669T>Ap.W557R21
8COSM520KRASsoft tissue,stomach,gastrointestinal stromal tumour,epithelioidc.35G>Tp.G12V21
9COSM1255KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1676T>Cp.V559A21
10COSM1154KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1491G>Ap.V497V21
11COSM736PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2525A>Tp.D842V21
12COSM12708KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2009C>Tp.T670I21
13COSM96893PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2533C>Tp.H845Y21
14COSM476BRAFsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1799T>Ap.V600E21
15COSM18681KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2467T>Gp.Y823D21
16COSM1221KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1669T>Gp.W557G21
17COSM1167KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1650A>Cp.K550N21
18COSM1290KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1727T>Cp.L576P21
19COSM1302KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1769G>Ap.S590N21
20COSM6146PIK3CAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.3137C>Tp.A1046V21
21COSM776PIK3CAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.3140A>Tp.H1047L21
22COSM12706KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1961T>Cp.V654A21
23COSM1227KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1670G>Cp.W557S21
24COSM96885KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1526A>Tp.K509I21
25COSM33903KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1730C>Tp.P577L21
26COSM22416PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1975A>Tp.N659Y21
27COSM17944KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1660G>Ap.E554K21
28COSM96889KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1513A>Cp.N505H21
29COSM96888KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1714G>Ap.D572N21
30COSM22379KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2458G>Cp.D820H21
31COSM1278KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1703A>Gp.Y568C21
32COSM22415PDGFRAsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1977C>Ap.N659K21
33COSM19216KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1674G>Cp.K558N21
34COSM1253KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1676T>Gp.V559G21
35COSM24749KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1690A>Cp.N564H21
36COSM1297KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1751T>Cp.F584S21
37COSM1243KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1674G>Ap.K558K21
38COSM1321KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2466T>Ap.N822K21
39COSM19109KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2464A>Tp.N822Y21
40COSM25065KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1940T>Cp.L647P21
41COSM1166KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1649A>Gp.K550R21
42COSM1219KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1669T>Cp.W557R21
43COSM24750KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1699A>Cp.N567H21
44COSM1184KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.1655T>Ap.M552K21
45COSM12709KITsoft tissue,stomach,gastrointestinal stromal tumour,spindlec.2460T>Ap.D820E21
46COSM308543KITsoft tissue,stomach,gastrointestinal stromal tumour,spindle and epithelioidc.1711A>Cp.I571L21
47COSM19325PDGFRAsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.1765C>Tp.P589S18
48COSM19324PDGFRAsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.2464C>Ap.R822S18
49COSM133700KITsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.1671G>Cp.W557C18
50COSM12710KITsoft tissue,small intestine,gastrointestinal stromal tumour,spindlec.2458G>Tp.D820Y18

Copy number variations for Gastrointestinal Stromal Tumor from CNVD:

6 (show top 50)    (show all 117)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11335211125000000LossGastrointestinal stromal cancer
21335311125000000LossGastrointestinal stromal cancer
31335411125000000LossGastrointestinal stromal cancer
4137661128000000LossGastrointestinal stromal cancer
5142711106334457114964386LossAMPD1Gastrointestinal stromal cancer
6142721106334457114964386LossAP4B1Gastrointestinal stromal cancer
7142731106334457114964386LossBCAS2Gastrointestinal stromal cancer
8164341124300000247249719GainGastrointestinal stromal cancer
9173881142600000147000000GainPEX11BGastrointestinal stromal cancer
102928812300000117600000LossGastrointestinal stromal cancer
113696618412966595422234LossRWDD3Gastrointestinal stromal cancer
1238126199947682100601821LossAGLGastrointestinal stromal cancer
1338127199947682100601821LossHIAT1Gastrointestinal stromal cancer
14445271058788206526558LossFBXO18Gastrointestinal stromal cancer
15445281058788206526558LossPFKFB3Gastrointestinal stromal cancer
16445291058788206526558LossRBM17Gastrointestinal stromal cancer
17458521074900000135534747LossGastrointestinal stromal cancer
184850711153700000Copy numberGastrointestinal stromal cancer
1966050122499108925698435DeletionKRASGastrointestinal stromal cancer
20670671235800000133851895GainGastrointestinal stromal cancer
2170005125702181685836547DeletionRAP1BGastrointestinal stromal cancer
22739001298322858130692602DeletionRANGastrointestinal stromal cancer
237469213110300000115169878LossGastrointestinal stromal cancer
24752471318400000105800000LossGastrointestinal stromal cancer
2575347131919823722523922DeletionLATS2Gastrointestinal stromal cancer
2675669132253620231430096DeletionRNF6Gastrointestinal stromal cancer
2777894134801127654590729DeletionTRIM13Gastrointestinal stromal cancer
2877895134801127654590729DeletionINTS6Gastrointestinal stromal cancer
2978534135252385372250500GainTDRD3Gastrointestinal stromal cancer
3079527137316088193888882GainC13orf7Gastrointestinal stromal cancer
3180767139740402199434703LossCLYBLGastrointestinal stromal cancer
3280768139740402199434703LossSTK24Gastrointestinal stromal cancer
3380769139740402199434703LossTM9SF2Gastrointestinal stromal cancer
34828331417600000107349540LossGastrointestinal stromal cancer
35828341417600000107349540LossGastrointestinal stromal cancer
36830131419100000106368585LossGastrointestinal stromal cancer
37831781419365081106329840LossOXA1LGastrointestinal stromal cancer
38831791419365081106329840LossPPP2R5EGastrointestinal stromal cancer
3984716143394277934940779LossC14orf10Gastrointestinal stromal cancer
4084717143394277934940779LossC14orf24Gastrointestinal stromal cancer
4185081143858582338760942DeletionPNNGastrointestinal stromal cancer
4286405145928447261286479DeletionPPM1AGastrointestinal stromal cancer
4387231147247021673993089LossC14orf168Gastrointestinal stromal cancer
4487232147247021673993089LossPSEN1Gastrointestinal stromal cancer
4587233147247021673993089LossZADH1Gastrointestinal stromal cancer
4687234147247021673993089LossZFYVE1Gastrointestinal stromal cancer
4787235147247021673993089LossZNF410Gastrointestinal stromal cancer
4887381147312625589981048DeletionSEL1LGastrointestinal stromal cancer
4987752147688927477394297LossC14orf133Gastrointestinal stromal cancer
5087753147688927477394297LossC14orf156Gastrointestinal stromal cancer

Expression for genes affiliated with Gastrointestinal Stromal Tumor

About this section
Search GEO for disease gene expression data for Gastrointestinal Stromal Tumor.

Pathways for genes affiliated with Gastrointestinal Stromal Tumor

About this section

Pathways related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathwaysScoreTop Affiliating Genes
110.3PDGFRA, PDGFRB
210.1ACTC1, KIT, PDGFRA
310.1NTRK3, PDGFRA, PDGFRB
4
Show member pathways
10.1FLT3, KIT, PDGFRB
510.1CD34, KIT, KITLG
610.1CD34, FLT3, KIT
710.1CD34, FLT3, KIT
810.1PDGFRA, S100B, VIM
910.1ACTC1, DES, VIM
10
Show member pathways
10.0SDHA, SDHB, SDHC, SDHD
11
Show member pathways
10.0KIT, KITLG, PDGFRA, PDGFRB
1210.0CD34, FLT3, KIT, KITLG
1310.0CD34, FLT3, KIT, KITLG
149.9FLT3, KIT, NTRK3, PDGFRA, PDGFRB
15
Show member pathways
9.9ENO2, SDHA, SDHB, SDHC, SDHD
16
Show member pathways
9.9ABL1, KIT, KITLG, PDGFRA, PDGFRB
17
Show member pathways
9.8ACTC1, FLT3, KIT, NTRK3, PDGFRA, PDGFRB
189.7ABL1, FLT3, KIT, KITLG, PDGFRA, PDGFRB
199.7ABL1, FLT3, KIT, KITLG, PDGFRA, PDGFRB
20
Show member pathways
9.7ENO2, MTHFR, SDHA, SDHB, SDHC, SDHD
21
Show member pathways
9.6FLT3, KIT, KITLG, NTRK3, PDGFRA, PDGFRB

GO Terms for genes affiliated with Gastrointestinal Stromal Tumor

About this section

Cellular components related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1respiratory chain complex IIGO:004527311.0SDHB, SDHC
2mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone)GO:000574910.8SDHA, SDHB, SDHC, SDHD
3intermediate filament cytoskeletonGO:004511110.6DES, MTRR, VIM
4cytoplasmGO:00057378.5ABL1, ACTC1, CD34, DES, ENO2, FLT3

Biological processes related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 29)
idNameGO IDScoreTop Affiliating Genes
1succinate metabolic processGO:000610510.9SDHA, SDHB
2metanephric glomerular capillary formationGO:007227710.9PDGFRA, PDGFRB
3positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayGO:003809110.9PDGFRA, PDGFRB
4methionine metabolic processGO:000655510.9MTHFR, MTRR
5platelet-derived growth factor receptor-beta signaling pathwayGO:003579110.9ABL1, PDGFRB
6myeloid progenitor cell differentiationGO:000231810.9FLT3, KIT
7ectopic germ cell programmed cell deathGO:003523410.9KIT, KITLG
8positive regulation of phospholipase C activityGO:001086310.9KIT, PDGFRA, PDGFRB
9Bergmann glial cell differentiationGO:006002010.8ABL1, VIM
10cardiac myofibril assemblyGO:005500310.7ACTC1, PDGFRA, PDGFRB
11phosphatidylinositol phosphorylationGO:004685410.6KIT, KITLG, PDGFRA, PDGFRB
12platelet-derived growth factor receptor signaling pathwayGO:004800810.6ABL1, PDGFRA, PDGFRB
13retina vasculature development in camera-type eyeGO:006129810.6PDGFRA, PDGFRB
14regulation of phosphatidylinositol 3-kinase signalingGO:001406610.6KIT, KITLG, PDGFRA, PDGFRB
15positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.6FLT3, KIT, PDGFRA, PDGFRB
16phosphatidylinositol-mediated signalingGO:004801510.6KIT, KITLG, PDGFRA, PDGFRB
17positive regulation of fibroblast proliferationGO:004814610.5ABL1, PDGFRA, PDGFRB
18positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.5FLT3, KIT, PDGFRA, PDGFRB
19hemopoiesisGO:003009710.4CD34, FLT3, KIT
20cell chemotaxisGO:006032610.4KIT, PDGFRA, PDGFRB
21positive regulation of MAP kinase activityGO:004340610.3FLT3, KIT, KITLG, PDGFRB
22tricarboxylic acid cycleGO:000609910.3SDHA, SDHB, SDHC, SDHD
23MAPK cascadeGO:000016510.2KIT, KITLG, PDGFRA, PDGFRB
24muscle filament slidingGO:003004910.2ACTC1, DES, VIM
25peptidyl-tyrosine phosphorylationGO:001810810.1ABL1, FLT3, KIT, NTRK3, PDGFRA, PDGFRB
26protein autophosphorylationGO:004677710.1ABL1, FLT3, KIT, NTRK3, PDGFRA, PDGFRB
27positive regulation of cell migrationGO:00303359.7KIT, NTRK3, PDGFRA, PDGFRB
28positive regulation of gene expressionGO:00106289.7ACTC1, CD34, KIT, NTRK3, VIM
29positive regulation of cell proliferationGO:00082849.6FLT3, KIT, KITLG, NTRK3, PDGFRA, PDGFRB

Molecular functions related to Gastrointestinal Stromal Tumor according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1vascular endothelial growth factor bindingGO:003808510.8PDGFRA, PDGFRB
2vascular endothelial growth factor-activated receptor activityGO:000502110.8FLT3, PDGFRA
3succinate dehydrogenase (ubiquinone) activityGO:000817710.8SDHA, SDHB
4succinate dehydrogenase activityGO:000010410.7SDHA, SDHC, SDHD
5platelet-derived growth factor bindingGO:004840710.6PDGFRA, PDGFRB
6phosphatidylinositol-4,5-bisphosphate 3-kinase activityGO:004693410.5KIT, KITLG, PDGFRA, PDGFRB
7ubiquinone bindingGO:004803910.5SDHB, SDHD
8transmembrane receptor protein tyrosine kinase activityGO:000471410.4FLT3, KIT, PDGFRA
9electron carrier activityGO:000905510.2SDHB, SDHC, SDHD
10flavin adenine dinucleotide bindingGO:005066010.0MTHFR, MTRR, SDHA
11Ras guanyl-nucleotide exchange factor activityGO:00050889.9KIT, KITLG, PDGFRA, PDGFRB

Sources for Gastrointestinal Stromal Tumor

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet